ESR1 and neoplasm: It has been proposed that a change in subtype for Luminal type tumours may be as a consequence of this ER-HER2 receptor cross-talk, where ER expression can limit PI3K pathway activity affecting HER2 pathway activation, whilst HER2 overexpression, largely due to copy number amplification, can lead to loss of ER gene expression.